108 related articles for article (PubMed ID: 25600566)
21. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Saloustros E; Malamos N; Kakolyris S; Boukovinas I; Papakotoulas P; Kentepozidis N; Ziras N; Georgoulias V;
Ann Oncol; 2015 Jul; 26(7):1333-40. PubMed ID: 25935793
[TBL] [Abstract][Full Text] [Related]
22. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients.
Fitzal F; Mittlboeck M; Steger G; Bartsch R; Rudas M; Dubsky P; Riedl O; Jakesz R; Gnant M
Ann Surg Oncol; 2012 Feb; 19(2):519-26. PubMed ID: 21743980
[TBL] [Abstract][Full Text] [Related]
24. Infiltrating lobular carcinoma of the breast: systemic treatment.
Farese SA; Aebi S
Breast Dis; 2008-2009; 30():45-52. PubMed ID: 19850995
[TBL] [Abstract][Full Text] [Related]
25. T1 invasive breast lobular tumor and ductal carcinoma with HER-2 positive characteristics: Is it rationale to use adjuvant trastuzumab?
Altundag K
J BUON; 2017; 22(4):1083. PubMed ID: 28952233
[No Abstract] [Full Text] [Related]
26. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
27. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer.
Arriagada R; Spielmann M; Koscielny S; Le Chevalier T; Delozier T; Rémé-Saumon M; Ducourtieux M; Tursz T; Hill C
Acta Oncol; 2005; 44(5):458-66. PubMed ID: 16118079
[TBL] [Abstract][Full Text] [Related]
28. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
[TBL] [Abstract][Full Text] [Related]
29. Acute Liver Failure Caused by Metastatic Breast Cancer: Can We Expect Some Results from Chemotherapy?
Giuliani J; Bonetti A
Dig Dis Sci; 2015 Aug; 60(8):2541-3. PubMed ID: 26088368
[No Abstract] [Full Text] [Related]
30. Response to neoadjuvant chemotherapy in patients with advanced breast cancer: a local hospital experience.
Khokher S; Mahmood S; Khan SA
Asian Pac J Cancer Prev; 2010; 11(2):303-8. PubMed ID: 20843105
[TBL] [Abstract][Full Text] [Related]
31. Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older.
Balasubramanian BA; Gandhi SK; Demissie K; August DA; Kohler B; Osinubi OY; Rhoads GG
Cancer Control; 2007 Jan; 14(1):63-8. PubMed ID: 17242672
[TBL] [Abstract][Full Text] [Related]
32. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
Piedbois P; Serin D; Priou F; Laplaige P; Greget S; Angellier E; Teissier E; Berdah JF; Fabbro M; Valenza B; Herait P; Jehl V; Buyse M
Ann Oncol; 2007 Jan; 18(1):52-57. PubMed ID: 17047001
[TBL] [Abstract][Full Text] [Related]
33. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
Calais G; Berger C; Descamps P; Chapet S; Reynaud-Bougnoux A; Body G; Bougnoux P; Lansac J; Le Floch O
Cancer; 1994 Aug; 74(4):1283-8. PubMed ID: 8055449
[TBL] [Abstract][Full Text] [Related]
34. Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer.
Chan A; Willsher PC; Hastrich DJ; Anderson J; Barham T; Latham B; Redfern A; VAN DER Schaaf A; Thomson J; Joseph D; Ingram D
Asia Pac J Clin Oncol; 2012 Mar; 8(1):62-70. PubMed ID: 22369445
[TBL] [Abstract][Full Text] [Related]
35. [A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity].
Kashiwagi S; Kawajiri H; Noda S; Takashima T; Onoda N; Nakata B; Kato Y; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2775-7. PubMed ID: 21224709
[TBL] [Abstract][Full Text] [Related]
36. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
37. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.
Helvie MA; Joynt LK; Cody RL; Pierce LJ; Adler DD; Merajver SD
Radiology; 1996 Feb; 198(2):327-32. PubMed ID: 8596826
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
Yazilitas D; Sendur MA; Karaca H; Ozdemir N; Aksoy S; Berk V; Yazici O; Ozturk B; Ozkan M; Zengin N; Altundag K
Asian Pac J Cancer Prev; 2015; 16(4):1471-7. PubMed ID: 25743817
[TBL] [Abstract][Full Text] [Related]
39. Typing breast cancer following primary chemotherapy.
Carder P
Histopathology; 1999 Dec; 35(6):584-5. PubMed ID: 10583584
[No Abstract] [Full Text] [Related]
40. Gallbladder metastases of breast cancer: from clinical-pathological patterns to diagnostic and therapeutic strategy.
Di Vita M; Zanghì A; Lanzafame S; Cavallaro A; Piccolo G; Berretta M; Grosso G; Cappellani A
Clin Ter; 2011; 162(5):451-6. PubMed ID: 22041804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
